Amgen's SWOT analysis: stock outlook amid obesity drug race, pipeline progress
Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors
Shares of Bio-Techne Corp. shed 3.71% to $71.83 Wednesday, on what proved to be an all-around dismal trading session for the ...
JD Supra11h
Amgen and Celltrion Settle Denosumab BPCIA Case
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
bovnews13h
What’s Causing Amgen Inc (AMGN) Stock’s -16.29% Drop Over the Last Six Months?
Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...
The Pharma Letter17h
Amgen and Celltrion settle biosimilars patent dispute
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
Healio19h
‘We applaud CMS’: Two more rheumatology drugs bound for Medicare price negotiation
The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...
Yahoo Finance19h
Here's Why Amgen (AMGN) is a Strong Value Stock
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health ...